Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 6, 2009, Pages 1083-1088

  Segarra, Alfons ^a   Praga, Manuel ^b   Ramos, Natalia ^a   Polanco, Natalia ^b   Cargol, Isabel ^a   Gutierrez Solis, Elena ^b   Gomez, M Rosa ^a   Montoro, Bruno ^a   Camps, Joaquim ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CD19 ANTIGEN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS; CALCINEURIN; DRUG DERIVATIVE; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; LONG TERM CARE; LOW DRUG DOSE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROTEINURIA; RELAPSE; REMISSION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; BIOPSY; CLINICAL TRIAL; DRUG ANTAGONISM; KIDNEY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; WITHDRAWAL SYNDROME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CALCINEURIN; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROTEINURIA; REMISSION INDUCTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 69249219337     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06041108     Document Type: Article

References (26)

1. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960-966, 1992
2. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
3. Wu Q, Jinde K, Nishina M, Tanabe R, Endoh M, Okada Y, Sakai H, Kurokawa K: Analysis of prognostic predictors in idiopathic membranous nephropathy. Am J Kidney Dis 37: 380-387, 2001
4. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23: 324-332, 2003
5. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47:1130 -1135, 1995
6. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
7. Praga M, Barrio V, Juarez GF, Luno, J: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71:924 -930, 2007
8. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D: Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 21: 3127-3132, 2006
9. Kerjaschki D, Farquhar MG: Immunocytochemical localization of the Heymann nephritis antigen (Gp330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157: 667-686, 1983
10. Ronco P, Debiec H: New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15: 258-263, 2006
11. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, Rastaldi MP, Kretzler M: CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 18: 328-333, 2005
12. Biancone L, Andres G, Ahn H, DeMartino C, Stamenkovic I: Inhibition of the CD40-CD40 ligand pathway prevents murine membranous glomerulonephritis. Kidney Int 48: 458-468, 1995
13. -Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, et al: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
14. Silverman GJ: Anti-CD20 therapy and autoimmune disease: Therapeutic opportunities and evolving insights. Front Biosci 12: 2194-2206, 2007
15. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
16. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M: Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
17. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, Remuzzi G: Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006
18. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937, 2007
19. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008
20. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997
21. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998
22. Grillo-López AJ: Rituximab: An insider's historical perspective. Semin Oncol 27[suppl 12]: 9-16, 2000
23. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004
24. Salama AD, Pusey CD: Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2: 221-230, 2006
25. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR: A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol Nov 7. [Epub ahead of print], 2008
26. Fox RI: FDA alert for rituximab in patients with systemic lupus erythematosus. Medscape Rheumatol 2007